(Q36442322)

14 August 2017

1 reference

title

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia (English)

1 reference

14 August 2017

0 references

Josep Maria Haro

1

0 references

Luis Salvador-Carulla

object named as

Luis Salvador-Carulla

series ordinal

2

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

20

1 reference

14 August 2017

4

1 reference

14 August 2017

293-301

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200620040-00003

14 August 2017

0 references

cites work

Psychopharmacologic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00003

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00003

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00003

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00003

Clozapine: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00003

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

21 January 2018

1 reference

12 December 2020

Selection Bias in Clinical Trials With Antipsychotics

1 reference

12 December 2020

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

1 reference

12 December 2020

Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia

1 reference

12 December 2020

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Information processing and neuroleptic response in acute and stabilized schizophrenic patients

1 reference

12 December 2020

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

12 December 2020

Therapeutic Antagonism Between Anticholinergics and Neuroleptics: Possible Involvement of Cholinergic Mechanisms in Schizophrenia

1 reference

12 December 2020

Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels

1 reference

12 December 2020

The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.

1 reference

12 December 2020

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

12 December 2020

Mechanisms of antipsychotic-induced weight gain

1 reference

12 December 2020

Extrapyramidal side effects are unacceptable

1 reference

12 December 2020

Spotlight on amisulpride in schizophrenia

1 reference

12 December 2020

Olanzapine for schizophrenia.

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Predictors of noncompliance in patients with schizophrenia.

1 reference

12 December 2020

The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital

1 reference

12 December 2020

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

1 reference

12 December 2020

Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.

1 reference

12 December 2020

A comparison of observational studies and randomized, controlled trials

1 reference

12 December 2020

Dosing and switching strategies for quetiapine fumarate

1 reference

12 December 2020

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

12 December 2020

Movement disorders associated with atypical antipsychotic drugs

1 reference

12 December 2020

Effects of anticholinergic medication on memory in schizophrenia.

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

1 reference

12 December 2020

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Depressive and negative symptoms in schizophrenia: different effects on clinical features.

1 reference

12 December 2020

Dropout rates in randomised antipsychotic drug trials

1 reference

12 December 2020

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials

1 reference

12 December 2020

Pharmacologic advances in the treatment of schizophrenia

1 reference

12 December 2020

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

1 reference

12 December 2020

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

12 December 2020

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

12 December 2020

Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study

1 reference

12 December 2020

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina

1 reference

12 December 2020

Effects of newer antipsychotics on extrapyramidal function

1 reference

12 December 2020

The implications of weight changes with antipsychotic treatment

1 reference

12 December 2020

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

12 December 2020

Antipsychotic drugs and relapse prevention

1 reference

12 December 2020

Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

12 December 2020

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

12 December 2020

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

1 reference

12 December 2020

10.2165/00023210-200620040-00003

Identifiers

DOI

1 reference

PubMed ID

16599647

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16599647